State Street Corp Boosts Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

State Street Corp grew its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 9.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 907,607 shares of the medical instruments supplier’s stock after buying an additional 77,506 shares during the period. State Street Corp owned 3.71% of ICU Medical worth $165,384,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC lifted its position in shares of ICU Medical by 441.7% during the 2nd quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock valued at $691,000 after buying an additional 4,744 shares during the last quarter. LMR Partners LLP purchased a new position in shares of ICU Medical during the 3rd quarter valued at $3,884,000. Savant Capital LLC purchased a new position in shares of ICU Medical during the 2nd quarter valued at $431,000. First Eagle Investment Management LLC purchased a new position in shares of ICU Medical during the 2nd quarter valued at $3,479,000. Finally, MetLife Investment Management LLC lifted its position in shares of ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after buying an additional 6,981 shares during the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other ICU Medical news, COO Christian B. Voigtlander sold 1,430 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total value of $225,940.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director David C. Greenberg sold 972 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $158.11, for a total value of $153,682.92. Following the completion of the transaction, the director now owns 5,037 shares in the company, valued at $796,400.07. This represents a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,364 shares of company stock worth $6,869,878 in the last ninety days. 6.70% of the stock is currently owned by insiders.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $161.64 on Friday. The firm has a market capitalization of $3.96 billion, a P/E ratio of -35.37 and a beta of 0.62. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The stock’s 50-day simple moving average is $171.12 and its two-hundred day simple moving average is $150.98. ICU Medical, Inc. has a twelve month low of $86.80 and a twelve month high of $196.26.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ICUI shares. Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. KeyCorp boosted their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Raymond James boosted their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, ICU Medical currently has an average rating of “Moderate Buy” and an average target price of $177.25.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.